Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Myocardial infarction (MI) is a major contributor to morbidity and mortality in China. The
goal of this interventional, randomised controlled clinical trial is to evaluate the
effectiveness and safety of a single administration of Nivolumab to the patients presenting
with an acute anterior ST-segmental elevated myocardial infarction. Researchers will
investigate if Nivolumab treatment can effectively and safely reduce infarct size as well as
improve cardiac function of the patients with acute myocardial infarction.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University